CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008

PALO ALTO, Calif., July 22 CA-CV-Thera-Conf-Call


PALO ALTO, Calif., July 22 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
(Nasdaq: CVTX) today announced that it will release second quarter financial
results for 2008 after the market closes on Thursday, July 31, 2008.  Company
management will webcast a conference call at 5:00 p.m. EDT, 2:00 p.m. PDT, on
the company's website.


To access the live webcast, please log on to the Company's website at
www.cvt.com and go to the Investor Information section. Alternatively,
domestic callers may participate in the conference call by dialing
(866) 524-6241, and international callers may participate in the conference
call by dialing (706) 679-3061.  Webcast and telephone replays of the
conference call will be available approximately two hours after the completion
of the call through Thursday, August 7, 2008. Domestic callers can access the
replay by dialing (800) 642-1687, and international callers can access the
replay by dialing (706) 645-9291; the PIN access number is 56235490.



About CV Therapeutics


CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company primarily focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small molecule
drugs for the treatment of cardiovascular diseases.


CV Therapeutics' approved products in the United States include Ranexa(R)
(ranolazine extended-release tablets), indicated for the treatment of chronic
angina in patients who have not achieved an adequate response with other
antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a
pharmacologic stress agent in radionuclide myocardial perfusion imaging in
patients unable to undergo adequate exercise stress.  Ranolazine is approved
for use in the European Union as add-on therapy for the symptomatic treatment
of patients with stable angina pectoris who are inadequately controlled or
intolerant to first-line antianginal therapies.



SOURCE  CV Therapeutics, Inc.